Rhabdomyosarcoma, a cancer of skeletal muscle lineage, is the most common soft-tissue sarcoma in children1. Major subtypes of rhabdomyosarcoma include alveolar (ARMS) and embryonal (ERMS) tumors2,3. Whereas ARMS tumors typically contain translocations generating PAX3-FOXO1 or PAX7-FOXO1 fusions that block terminal myogenic differentiation4,5,6, no functionally comparable genetic event has been found in ERMS tumors. Here we report the discovery, through whole-exome sequencing, of a recurrent somatic mutation encoding p.Leu122Arg in the myogenic transcription factor MYOD1 in a distinct subset of ERMS tumors with poor outcomes that also often contain mutations altering PI3K-AKT pathway components. Previous mutagenesis studies had shown that MYOD1 with a p.Leu122Arg substitution can block wild-type MYOD1 function and bind to MYC consensus sequences7, suggesting a possible switch from differentiation to proliferation. Our functional data now confirm this prediction. Thus, MYOD1 p.Leu122Arg defines a subset of rhabdomyosarcomas eligible for high-risk protocols and the development of targeted therapeutics.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gene Expression Omnibus
Sequence Read Archive
We thank H. Hosoi (Kyoto Prefectural University of Medicine) and S. Tanaka and M. Tsuda (both at Hokkaido University) for providing cell lines. We also thank T. Akagi and K. Sasai (both at KAN Research Institute, Inc.) for providing the pcx4bleo plasmid. We are also grateful to J. Zhao for technical assistance with microarray analysis, to L. Borsu for assistance with Sequenom analyses and to E. de Stanchina and R. Tieu for the xenograft studies. This work was supported by a generous donation from M.B. Zuckerman (M.L.), by NIH P01 CA047179 (S.S.), by NCI P50 CA140146 (M.L., N.D.S. and S.S.), by a National Center for Research Resources (NCRR) Clinical Translational Science Center grant (M.P. and N.D.S.) and by the Virginia and Daniel K. Ludwig Trust for Cancer Research (J.A.F.). S.K. was supported in part by the Yasuda Medical Foundation and the HIROKO International Academic Exchange Foundation. F.G.B. is supported by the Intramural Research Program of the National Cancer Institute. The Memorial Sloan Kettering Cancer Center Sequenom facility was supported by the Anbinder Fund, and the Genomics and Bioinformatics Cores are supported by Cancer Center Core grant NCI P30 CA008748.
Integrated supplementary information
Complete lists of variant calls from next-generation sequencing.
About this article
Nature Genetics (2018)